Thoughts?

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages Iâ€“III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial - Nature Communications The authors previously reported the primary outcomes of a randomized phase II trial comparing neoadjuvant durvalumab (anti-PD-L1) alone or in combination with stereotactic radiotherapy in patients with early-stage NSCLC. Here, the authors report the secondary outcomes of the trial and post hoc... www.nature.com

https://forums.studentdoctor.net/threads/thoughts.1489717/

Source: Student Doctor Network - December 29, 2023 Category: Universities & Medical Training Authors: Lamount Tags: Radiation Oncology Source Type: forums